RWP
ELDN icon

Revolve Wealth Partners’s Eledon Pharmaceuticals ELDN Stock Holding History

Revolve Wealth Partners’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.7K Hold
14,143
– – 0.01% 353
2026
Q1 		$43.6K Buy
+14,143
New +$33.3K 0.01% 229

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Revolve Wealth Partners's ELDN Position: Q2 2026 in Review

Revolve Wealth Partners held its Eledon Pharmaceuticals (ELDN) position steady in Q2 2026 at 14,143 shares worth $55.7K. The position accounts for 0.01% of the portfolio, ranked #353.

Revolve Wealth Partners first reported a position in ELDN in Q1 2026 and has held it in 2 quarters since. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Revolve Wealth Partners held 14,143 shares of Eledon Pharmaceuticals worth $55.7K as of Q2 2026.
  • Revolve Wealth Partners left its Eledon Pharmaceuticals share count unchanged in Q2 2026.
  • Eledon Pharmaceuticals made up 0.01% of Revolve Wealth Partners's portfolio in Q2 2026, its #353 holding.
  • Revolve Wealth Partners first reported a position in Eledon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Revolve Wealth Partners's 13F filing for Q2 2026, filed 9 Jul 2026.